I can explain it and have previously. There were multiple reagents used in one of 2 potency assays used in the trial. One of these reagents had inadequate QA and as a result was too variable in quality giving poor results. SI stated to me after the AGM that he thought the original assay was superior to the one that was accepted for the Adult trial. Analyzing the original trial data using potency assays with proper QA gives acceptable new data for consideration of the successful phase III trial.
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-162
-
- There are more pages in this discussion • 935 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
91.8¢ |
Change
-0.008(0.81%) |
Mkt cap ! $1.050B |
Open | High | Low | Value | Volume |
92.0¢ | 92.5¢ | 91.5¢ | $449.8K | 489.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
29 | 189245 | 91.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
92.0¢ | 51891 | 29 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
26 | 180015 | 0.915 |
21 | 211382 | 0.910 |
5 | 39324 | 0.905 |
43 | 365236 | 0.900 |
9 | 388314 | 0.895 |
Price($) | Vol. | No. |
---|---|---|
0.920 | 47676 | 26 |
0.925 | 94346 | 15 |
0.930 | 80611 | 7 |
0.935 | 130086 | 6 |
0.940 | 16560 | 4 |
Last trade - 11.40am 18/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |